Ascentage Pharma: Multiple clinical advances will be presented at the 2026 American Society of Hematology Annual Meeting, including an oral presentation for APG-5918.

Ascentage Pharma announced that multiple clinical and preclinical research advances have been selected for the 68th American Society of Hematology Annual Meeting, covering four assets: olverembatinib, China's first approved third-generation BCR-ABL inhibitor; lisaftoclax, China's first approved domestically developed Bcl-2 inhibitor; APG-5918, a PRC2/EED inhibitor; and APG-3288, a BTK degrader. Together they comprehensively demonstrate the company's deep footprint and global innovation strength in the hematologic oncology field. Notably, APG-5918 received an oral presentation upon its first disclosure of clinical data.